Dipyanone

Last updated
Dipyanone
Dipyanone.svg
Identifiers
  • 4,4-diphenyl-6-(1-pyrrolidinyl)-heptan-3-one
CAS Number
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C23H29NO
Molar mass 335.491 g·mol−1
3D model (JSmol)
  • CCC(=O)C(CC(C)N1CCCC1)(c1ccccc1)c1ccccc1

Dipyanone is an opioid analgesic which has been sold as a designer drug, first identified in Germany in 2021. [1] It is closely related to medically used drugs such as methadone, dipipanone and phenadoxone, but is slightly less potent. [2] [3]

See also

Related Research Articles

<span class="mw-page-title-main">Methadone</span> Opioid medication

Methadone, sold under the brand names Dolophine and Methadose among others, is a synthetic opioid agonist used for chronic pain and also for opioid use disorder. It is used to treat chronic pain, and it is also used to treat addiction to heroin or other opioids. Prescribed for daily use, the medicine relieves cravings and removes withdrawal symptoms. Withdrawal management using methadone can be accomplished in less than a month, or it may be done gradually over a longer period of time, or simply maintained for the rest of the patient's life. While a single dose has a rapid effect, maximum effect can take up to five days of use. After long-term use, in people with normal liver function, effects last 8 to 36 hours. Methadone is usually taken by mouth and rarely by injection into a muscle or vein.

<span class="mw-page-title-main">Oxycodone</span> Opioid medication

Oxycodone, sold under the brand name Roxicodone and OxyContin among others, is a semi-synthetic opioid used medically for treatment of moderate to severe pain. It is highly addictive and is a commonly abused drug. It is usually taken by mouth, and is available in immediate-release and controlled-release formulations. Onset of pain relief typically begins within fifteen minutes and lasts for up to six hours with the immediate-release formulation. In the United Kingdom, it is available by injection. Combination products are also available with paracetamol (acetaminophen), ibuprofen, naloxone, naltrexone, and aspirin.

<span class="mw-page-title-main">Hydrocodone/paracetamol</span> Combination pain relief drug

Hydrocodone/paracetamol is the combination of the pain medications hydrocodone and paracetamol (acetaminophen). It is used to treat moderate to severe pain. It is taken by mouth. Recreational use is common in the United States.

<span class="mw-page-title-main">Nortilidine</span> Chemical compound

Nortilidine is the major active metabolite of tilidine. It is formed from tilidine by demethylation in the liver. The racemate has opioid analgesic effects roughly equivalent in potency to that of morphine. The (1R,2S) isomer has NMDA antagonist activity. The drug also acts as a dopamine reuptake inhibitor. The reversed-ester of nortilidine is also known, as is the corresponding analogue with the cyclohexene ring replaced by cyclopentane, which have almost identical properties to nortilidine.

<span class="mw-page-title-main">Acetylfentanyl</span> Opioid analgesic

Acetylfentanyl is an opioid analgesic drug that is an analog of fentanyl. Studies have estimated acetylfentanyl to be 15 times more potent than morphine, which would mean that despite being somewhat weaker than fentanyl, it is nevertheless still several times stronger than pure heroin. It has never been licensed for medical use and instead has only been sold on the illicit drug market. Acetylfentanyl was discovered at the same time as fentanyl itself and had only rarely been encountered on the illicit market in the late 1980s. However, in 2013, Canadian police seized 3 kilograms of acetylfentanyl. As a μ-opioid receptor agonist, acetylfentanyl may serve as a direct substitute for oxycodone, heroin or other opioids. Common side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially fatal respiratory depression. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.

<span class="mw-page-title-main">MDMB-CHMICA</span> Chemical compound

'MDMB-CHMICAa' is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. While MDMB-CHMICA was initially sold under the name "MMB-CHMINACA", the compound corresponding to this code name (i.e. the isopropyl instead of t-butyl analogue of MDMB-CHMINACA) has been identified on the designer drug market in 2015 as AMB-CHMINACA.

<span class="mw-page-title-main">Mitragynine</span> Opioid analgesic compound

Mitragynine is an indole-based alkaloid and the most abundant active alkaloid in the Southeast Asian plant Mitragyna speciosa, commonly known as kratom. The total alkaloid concentration in dried leaves ranges from 0.5 to 1.5%. In Thai varieties, mitragynine is the most abundant component while 7-hydroxymitragynine is a minor constituent. In Malaysian kratom varieties, mitragynine is present at lower concentration. Such preparations are orally consumed and typically involve dried kratom leaves which are brewed into tea or ground and placed into capsules. Mitragynine consumption for medicinal and recreation purposes dates back centuries, although early use was primarily limited to Southeast Asian countries such as Indonesia and Thailand where the plant grows indigenously. Recently, mitragynine use has spread throughout Europe and the Americas as both a recreational and medicinal drug. While research into the effects of kratom have begun to emerge, investigations on the active compound mitragynine are less common.

<span class="mw-page-title-main">Etodesnitazene</span> Chemical compound

Etodesnitazene is a benzimidazole derived opioid analgesic drug, which was originally developed in the late 1950s alongside etonitazene and a range of related derivatives. It is many times less potent than etonitazene itself, but still 70x more potent than morphine in animal studies. Corresponding analogues where the N,N-diethyl group is replaced by piperidine or pyrrolidine rings also retain significant activity. Etodesnitazene has been sold as a designer drug, first being identified in both Poland and Finland in March 2020.

<span class="mw-page-title-main">CUMYL-CBMINACA</span> Chemical compound

CUMYL-CBMINACA (SGT-277) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Germany in February 2020. It is illegal in Finland.

<span class="mw-page-title-main">2C-B-aminorex</span> Chemical compound

2C-B-aminorex (2C-B-AR) is a recreational designer drug with psychedelic effects. It is a substituted aminorex derivative which was first identified in Sweden in June 2019. Structurally, it is a hybrid of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and aminorex.

<span class="mw-page-title-main">5F-JWH-398</span> Chemical compound

5F-JWH-398 is a recreational designer drug which is classed as a synthetic cannabinoid. It is from the naphthoylindole family, and produces cannabis-like effects. It was legally sold in New Zealand from 2012 to 2014 under the psychoactive substances scheme but was discontinued in May 2014 following the end of the interim approval period under the Psychoactive Substances Act 2013. Subsequently, it has appeared on the illicit market around the world and was identified in Germany in May 2019.

The Trans-European Drug Information (TEDI) project is a European database compiling information from different drug checking services located on the European continent. The non-governmental organizations feeding into the database are referred to as the TEDI network.

<span class="mw-page-title-main">4-Cl-3-MMC</span> Chemical compound

4-Chloro-3-Methylmethcathinone (4-Cl-3-MMC) is a chemical compound from the substituted cathinone family. It has stimulant effects, and has been sold as a designer drug. It was first identified in Sweden in 2021. It is illegal in Italy and Finland, as well as under generic legislation in various other jurisdictions.

<span class="mw-page-title-main">4-HO-MALT</span> Chemical compound

4-HO-MALT (4-hydroxy-N-methyl-N-allyltryptamine) is a tryptamine derivative which has been sold as a designer drug, first being detected in Slovenia in 2021.

<span class="mw-page-title-main">3F-NEB</span> Substituted cathinone stimulant drug

3-Fluoro-N-ethylbuphedrone (3F-NEB) is a substituted cathinone derivative with stimulant effects which has been sold as a designer drug. It was first identified in Sweden in 2021.

<span class="mw-page-title-main">2-Me-PVP</span> Stimulant designer drug of the substituted cathinone class

2-Methyl-alpha-PVP (2-Me-PVP) is a substituted cathinone derivative with stimulant effects which has been sold as a designer drug. It was first identified in Sweden in 2021.

<span class="mw-page-title-main">Metaphedrine</span> Designer drug

3-Methylmethamphetamine (3-MMA) or Metaphedrine is an amphetamine derivative which has been sold as a designer drug, first being reported in Sweden in 2021.

<span class="mw-page-title-main">Deschloroclotizolam</span> Designer drug

Deschloroclotizolam is a thienotriazolodiazepine derivative which has been sold as a designer drug, first being identified in Sweden in 2021.

<span class="mw-page-title-main">CP 42,096</span> Cannabinoid agonist drug

CP 42,096 is an analgesic drug which acts as a cannabinoid agonist. It was developed by Pfizer in the 1980s as part of the research that led to the development of levonantradol, and is more potent than THC but less potent than newer compounds such as CP 55,244.

References

  1. European Monitoring Centre for Drugs and Drug Addiction. (June 2022). New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System (PDF). European Monitoring Centre for Drugs and Drug Addiction. doi:10.2810/882318 (inactive 2024-09-19). ISBN   978-92-9497-737-3.{{cite book}}: CS1 maint: DOI inactive as of September 2024 (link)
  2. Ofner P, Walton E (1950). "444. Search for new analgesics. Part IV. Variations in the basic side-chain of amidone". Journal of the Chemical Society (Resumed): 2158. doi:10.1039/JR9500002158.
  3. Lenz GR, Evans SM, Walters DE, Hopfinger AJ (1986). Opiates. Academic Press. pp. 406–407. ISBN   978-0-12-443830-9.